Literature DB >> 7118508

Spectral sensitivity and color discrimination changes in glaucoma and glaucoma-suspect patients.

A J Adams, R Rodic, R Husted, R Stamper.   

Abstract

Color vision changes may occur early in the course of glaucoma and may precede visual field loss. Glaucoma suspects, having raised intraocular pressure and no diagnostic optic nerve head or visual field changes, may also have color vision loss. Unfortunately, the instruments used in the studies that have demonstrated these color vision changes were not feasible for routine clinical use; likewise, the studies did not carefully control for the effects of small pupil size and age or did not point to the underlying mechanisms responsible. We studied 19 glaucoma patients, 19 glaucoma suspects, and age-matched controls for each group by means of the Farnsworth D-15 panel test, a desaturated version of the D-15 test, and by measures of spectral increment threshold. Minor modifications of the Farnsworth D-15 panel test produce highly significant differentiation of glaucoma and glaucoma-suspect patients from age-matched normal groups. Further, spectral increment thresholds, with a two-degree spectral target flashed at either 1 or 25 Hz on a bright white background, show that both achromatic and chromatic sensitivity are significantly reduced when compared with their age-matched normals. Pupil size does not seem to be a significant factor. These results suggest that the function of two different ganglion cell populations is affected in glaucoma and that glaucoma may produce functional loss in the central foveal area earlier in the disease process than previously believed.

Entities:  

Mesh:

Year:  1982        PMID: 7118508

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  20 in total

Review 1.  Acquired colour vision defects in glaucoma-their detection and clinical significance.

Authors:  M Pacheco-Cutillas; D F Edgar; A Sahraie
Journal:  Br J Ophthalmol       Date:  1999-12       Impact factor: 4.638

2.  Topography of the chromatic pattern-onset VEP.

Authors:  Christina Gerth; Peter B Delahunt; Michael A Crognale; John S Werner
Journal:  J Vis       Date:  2003       Impact factor: 2.240

3.  Short wavelength automated perimetry and tamoxifen use.

Authors:  A Eisner; D F Austin; J R Samples
Journal:  Br J Ophthalmol       Date:  2004-01       Impact factor: 4.638

4.  Color pattern-reversal visual evoked potential in eyes with ocular hypertension and primary open-angle glaucoma.

Authors:  Y H Shih; Z J Huang; C E Chang
Journal:  Doc Ophthalmol       Date:  1991       Impact factor: 2.379

5.  Color axis evaluation of the Farnsworth Munsell 100-hue test in primary open-angle glaucoma and normal-pressure glaucoma.

Authors:  W M Budde; A Jünemann; M Korth
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

6.  Automated perimetry and short wavelength sensitivity in patients with asymmetric intraocular pressures.

Authors:  R A Lewis; C A Johnson; A J Adams
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-05       Impact factor: 3.117

7.  Correlation between blue-on-yellow perimetry and scanning laser polarimetry with variable corneal compensation measurements in primary open-angle glaucoma.

Authors:  Yisheng Zhong; Liping Chen; Yu Cheng; Ping Huang
Journal:  Jpn J Ophthalmol       Date:  2009-12-18       Impact factor: 2.447

8.  Clinical detection of abnormalities in central vision in chronic simple glaucoma using contrast sensitivity.

Authors:  J E Ross
Journal:  Int Ophthalmol       Date:  1985-09       Impact factor: 2.031

9.  Detection of optic nerve damage in ocular hypertension.

Authors:  J E Ross; A J Bron; B C Reeves; P G Emmerson
Journal:  Br J Ophthalmol       Date:  1985-12       Impact factor: 4.638

10.  Blue-yellow and standard pattern visual evoked potentials in phakic and pseudophakic glaucoma patients and controls.

Authors:  Matthias Fuest; Jule Kieckhoefel; Babac Mazinani; David Kuerten; Antonis Koutsonas; Eva Koch; Peter Walter; Niklas Plange
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-09-04       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.